{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T10:14:21Z","timestamp":1769940861765,"version":"3.49.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,8]]},"DOI":"10.7759\/cureus.87558","type":"journal-article","created":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T13:56:49Z","timestamp":1752069409000},"source":"Crossref","is-referenced-by-count":1,"title":["Autologous Hematopoietic Stem Cell Transplantation (aHSCT) in a 56-Year-Old Filipino Female With Relapsing and Remitting Multiple Sclerosis: A Case Report"],"prefix":"10.7759","author":[{"given":"Jon Stewart H","family":"Dy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela Marie M","family":"Cope","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cymbeline","family":"Perez-Santiago","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco F","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Multiple sclerosis and other neuroimmunologic disorders","author":"Ropper AH","year":"2023","unstructured":"Ropper AH, Samuels MA, Klein JP, Prasad S. Multiple sclerosis and other neuroimmunologic disorders. Adams and Victor's Principles of Neurology. McGraw-Hill Education, New York, NY; 2023."},{"key":"ref2","unstructured":"ECTRIMS. McDonald Diagnostic Criteria. (2024). Accessed. June 13, 2025: https:\/\/ectrims.eu\/mcdonald-diagnostic-criteria."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.824926","article-title":"Therapeutic Advances in multiple sclerosis","volume":"13","author":"Yang JH","year":"2022","unstructured":"Yang JH, Rempe T, Whitmire N, Dunn-Pirio A, Graves JS. Therapeutic Advances in multiple sclerosis. Front Neurol. 2022, 13:824926. 10.3389\/fneur.2022.824926","journal-title":"Front Neurol"},{"key":"ref4","unstructured":"Philippine National Formulary Essential Medicines List. (2019). Accessed. June 13, 2025: https:\/\/www.philhealth.gov.ph\/partners\/providers\/pdf\/PNF-EML_11022022.pdf."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.4025","article-title":"Autologous hematopoietic stem cell transplant in multiple sclerosis: recommendations of the National Multiple Sclerosis Society","volume":"78","author":"Miller AE","year":"2021","unstructured":"Miller AE, Chitnis T, Cohen BA, Costello K, Sicotte NL, Stacom R. Autologous hematopoietic stem cell transplant in multiple sclerosis: recommendations of the National Multiple Sclerosis Society. JAMA Neurol. 2021, 78:241-6. 10.1001\/jamaneurol.2020.4025","journal-title":"JAMA Neurol"},{"key":"ref6","unstructured":"GetMeds. (2025). Accessed. June 13, 2025: https:\/\/getmeds.ph\/online-medicine\/allergy\/finmod-500-mcg."},{"key":"ref7","unstructured":"The Philippine Drug Price Reference Index. (2021). Accessed. June 13, 2025: https:\/\/caro.doh.gov.ph\/wp-content\/uploads\/2021\/09\/2021DPRI-as-of-9-17-2021.pdf."},{"key":"ref8","unstructured":"St. Luke's Medical Center. (2025). Accessed. June 13, 2025: https:\/\/www.stlukes.com.ph\/."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005347","article-title":"Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology","volume":"90","author":"Rae-Grant A","year":"2018","unstructured":"Rae-Grant A, Day GS, Marrie RA, et al.. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018, 90:777-88. 10.1212\/WNL.0000000000005347","journal-title":"Neurology"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2017.81","article-title":"Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis","volume":"13","author":"Muraro PA","year":"2017","unstructured":"Muraro PA, Martin R, Mancardi GL, Nicholas R, Sormani MP, Saccardi R. Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis. Nat Rev Neurol. 2017, 13:391-405. 10.1038\/nrneurol.2017.81","journal-title":"Nat Rev Neurol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001329","article-title":"Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial","volume":"84","author":"Mancardi GL","year":"2015","unstructured":"Mancardi GL, Sormani MP, Gualandi F, et al.. Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial. Neurology. 2015, 84:981-8. 10.1212\/WNL.0000000000001329","journal-title":"Neurology"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.18743","article-title":"Effect of nonmyeloablative hematopoietic stem cell transplantation vs continued disease-modifying therapy on disease progression in patients with relapsing-remitting multiple sclerosis: a randomized clinical trial","volume":"321","author":"Burt RK","year":"2019","unstructured":"Burt RK, Balabanov R, Burman J, et al.. Effect of nonmyeloablative hematopoietic stem cell transplantation vs continued disease-modifying therapy on disease progression in patients with relapsing-remitting multiple sclerosis: a randomized clinical trial. JAMA. 2019, 321:165-74. 10.1001\/jama.2018.18743","journal-title":"JAMA"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2025.106542","article-title":"Comparative analysis of five-year clinical outcomes of autologous hematopoietic stem cell transplantation and alemtuzumab in multiple sclerosis patients","volume":"100","author":"Manazo\u011flu HC","year":"2025","unstructured":"Manazo\u011flu HC, \u0130\u015fkan G, G\u00fcnd\u00fcz T, et al.. Comparative analysis of five-year clinical outcomes of autologous hematopoietic stem cell transplantation and alemtuzumab in multiple sclerosis patients. Mult Scler Relat Disord. 2025, 100:106542. 10.1016\/j.msard.2025.106542","journal-title":"Mult Scler Relat Disord"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2023.1184","article-title":"Comparative effectiveness of autologous hematopoietic stem cell transplant vs fingolimod, natalizumab, and ocrelizumab in highly active relapsing-remitting multiple sclerosis","volume":"80","author":"Kalincik T","year":"2023","unstructured":"Kalincik T, Sharmin S, Roos I, et al.. Comparative effectiveness of autologous hematopoietic stem cell transplant vs fingolimod, natalizumab, and ocrelizumab in highly active relapsing-remitting multiple sclerosis. JAMA Neurol. 2023, 80:702-13. 10.1001\/jamaneurol.2023.1184","journal-title":"JAMA Neurol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/ana.27247","article-title":"Effectiveness of autologous hematopoietic stem cell transplantation versus alemtuzumab and ocrelizumab in relapsing multiple sclerosis: a single center cohort study","author":"Muraro PA","year":"2025","unstructured":"Muraro PA, Zito A, Signori A, et al.. Effectiveness of autologous hematopoietic stem cell transplantation versus alemtuzumab and ocrelizumab in relapsing multiple sclerosis: a single center cohort study. Ann Neurol. 2025, 10.1002\/ana.27247","journal-title":"Ann Neurol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2025.01.250","article-title":"Evaluation of the effect of autologous hematopoietic stem cell transplant on symptom severity using Msws-12, Amsq and symptomscreen in multiple sclerosis patients","volume":"31","author":"Cruz-P\u00e9rez GE","year":"2025","unstructured":"Cruz-P\u00e9rez GE, Gallardo-Perez MM, Garc\u00eda-V\u00e9lez D, et al.. Evaluation of the effect of autologous hematopoietic stem cell transplant on symptom severity using Msws-12, Amsq and symptomscreen in multiple sclerosis patients. Transplant Cell Therapy. 2025, 31:S163. 10.1016\/j.jtct.2025.01.250","journal-title":"Transplant Cell Therapy"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16427","article-title":"Exploring the therapeutic potential of autologous hematopoietic stem cell transplantation in progressive multiple sclerosis-a systematic review","volume":"31","author":"Braun B","year":"2024","unstructured":"Braun B, Fischbach F, Pfeffer LK, et al.. Exploring the therapeutic potential of autologous hematopoietic stem cell transplantation in progressive multiple sclerosis-a systematic review. Eur J Neurol. 2024, 31:e16427. 10.1111\/ene.16427","journal-title":"Eur J Neurol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1177\/13524585251315363","article-title":"Patient-reported outcomes of quality of life before and after autologous hematopoietic stem cell transplantation for multiple sclerosis","volume":"31","author":"Mitrache Desaga AC","year":"2025","unstructured":"Mitrache Desaga AC, Noui Y, Silfverberg T, Carlson K, Burman J. Patient-reported outcomes of quality of life before and after autologous hematopoietic stem cell transplantation for multiple sclerosis. Mult Scler. 2025, 31:455-63. 10.1177\/13524585251315363","journal-title":"Mult Scler"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102510","article-title":"The current status and challenges in multiple sclerosis management in the Philippines","volume":"46","author":"Ignacio KH","year":"2020","unstructured":"Ignacio KH, Espiritu AI, Jamora RD. The current status and challenges in multiple sclerosis management in the Philippines. Mult Scler Relat Disord. 2020, 46:102510. 10.1016\/j.msard.2020.102510","journal-title":"Mult Scler Relat Disord"},{"key":"ref20","unstructured":"Philippine Statistics Authority. Households Share 44.4 Percent of the Country's Total Health Spending in 2023. (2024). Accessed. June 13, 2025: https:\/\/psa.gov.ph\/content\/households- share-444-percent-countrys-total-health-spending-2023."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/385832-autologous-hematopoietic-stem-cell-transplantation-ahsct-in-a-56-year-old-filipino-female-with-relapsing-and-remitting-multiple-sclerosis-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T13:56:51Z","timestamp":1752069411000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/385832-autologous-hematopoietic-stem-cell-transplantation-ahsct-in-a-56-year-old-filipino-female-with-relapsing-and-remitting-multiple-sclerosis-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,8]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.87558","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,8]]}}}